Isoniazid News and Research

RSS

Second-line treatment for drug-resistant tuberculosis is as effective as first-line medicines

Patients who have drug-resistant tuberculosis (TB) have a similar microbiological response to bedaquiline-based second-line medications as patients with drug-sensitive TB taking first-line regimens, according to researchers at Weill Cornell Medicine in New York and GHESKIO Centers in Haiti.

27 Feb 2024

New study reveals turmeric and Tinospora Cordifolia reduce liver injury risk in TB patients

The effectiveness of herbs and alternative medicines in preventing liver injury induced by anti-tuberculosis (anti-TB) drugs.

16 Nov 2023

New TB treatments tackle the disease without wrecking your microbiome

Researchers in a study published in The Lancet Microbe examined how various tuberculosis treatment regimens affect the respiratory microbiome. They found that certain treatments control tuberculosis effectively while minimally impacting the diversity and health of the respiratory microbiome.

15 Oct 2023

Fighting tuberculosis: Breakthrough analysis reveals mixed strain infections

The drug-resistant genotypes in mixed strain infection (MSI) samples of Mycobacterium tuberculosis.

12 Oct 2023

Higher dose and shorter treatment of key antibiotic proven to be safe for TB patients

A higher dose and shorter treatment time of a cornerstone tuberculosis (TB) drug has proven to be safe for patients, according to a clinical trial led by researchers at St George's, University of London and results published in NEJM Evidence.

29 Aug 2023

Clinical trial of three-month TB treatment regimen closed due to high rate of unfavorable outcomes

The first clinical trial of a three-month tuberculosis (TB) treatment regimen is closing enrollment because of a high rate of unfavorable outcomes with the investigational course of treatment.

5 Jul 2023

Beyond expectations: study finds treatment success gap in drug-resistant Tuberculosis

Researchers performed a review of global treatment outcomes of drug-resistant Tuberculosis.

27 Jun 2023

Real-world management and outcomes of U.S. patients treated with BpaL for rifampin-resistant tuberculosis

Researchers reported on the treatment of rifampin-resistant tuberculosis in the United States using the FDA approved bedaquiline, pretomanid, and linezolid (BPaL) therapy.

1 Jun 2023

Revolution in MDR-TB treatment: Shorter all-oral regimens

Researchers reported on the evolution of multidrug-resistant tuberculosis (MDR-TB) therapy.

6 Apr 2023

The rapid diagnosis of drug-resistant and drug-sensitive tuberculosis using mass spectrometry and machine learning

In a recent study posted to the Preprints with The Lancet SSRN* server, a team of researchers in China developed a machine learning-based diagnostic tool to detect tuberculosis and drug-resistant tuberculosis using nanoparticle-enhanced laser desorption/ionization mass spectrometry (NPELDI MS) to determine metabolic fingerprints from serum samples.

28 Feb 2023

Study identifies a protein in Mycobacterium tuberculosis that contributes to drug tolerance

Weill Cornell Medicine researchers have identified a protein in Mycobacterium tuberculosis (Mtb) that contributes to drug tolerance, a phenomenon that allows bacteria to survive treatment with drugs that would normally kill them.

4 May 2022

Study explores decline in tuberculosis cases during COVID-19 pandemic in the United States

Researchers analyzed a pharmacy dataset to evaluate the 20% decrease in tuberculosis cases reported in 2020 by the US National Tuberculosis Surveillance System.

21 Mar 2022

ACTG announces launch of clinical trial evaluating a three-month TB treatment

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the launch of A5362 (CLO-FAST), a clinical trial studying a three-month clofazimine- and high-dose rifapentine-containing treatment regimen for people with drug-susceptible tuberculosis (TB).

10 Nov 2021

Weill Cornell receives NIH support to advance TB research

Tuberculosis (TB) is one of the deadliest infectious diseases in history and one of the few that naturally infects only humans.

4 Sep 2021

Study: Four-month regimen of anti-TB drugs works just as well as standard regimen

A new four-month regimen of anti-TB drugs that includes rifapentine and moxifloxacin works just as well as the standard six-month regimen, according to a study.

24 May 2021

Four months of multi-drug therapy for tuberculosis is as effective as standard regimen

Four months of multi-drug therapy that included rifapentine and moxifloxacin treated active tuberculosis (TB) as effectively as the standard six-month regimen in a multinational study, cutting treatment time by a third.

20 May 2021

Designing effective multidrug-resistant-TB treatments based on DNA sequencing

Globally, tuberculosis is the most common bacterial infectious disease leading to death. The pathogen causing tuberculosis, Mycobacterium tuberculosis, has a number of peculiarities. One is that it is growing very slowly.

3 May 2021

New drug cocktail offers hope to patients with highly drug-resistant tuberculosis

A new three-drug, all-oral, six-month treatment is providing hope to patients in Tajikistan with highly drug-resistant forms of tuberculosis, which until now had limited treatment options and poor prognosis.

3 Feb 2021

WHO revises definition of extensively drug-resistant tuberculosis

The definition of extensively drug-resistant tuberculosis (XDR-TB) has been revised by the World Health Organization's Global TB Programme, who have also defined pre-XDR-TB for the first time, highlighting the seriousness of these forms of TB.

1 Feb 2021

Overcoming pediatric drug-resistant TB crisis

World Children's Day marks the day, over three decades ago, on which world leaders adopted the historic Convention of the Rights of the Child, promising to every child to promote and protect their rights, including the right to life and the right to health.

30 Nov 2020